Hyperpolarized xenon‑129 MRI for imaging lung function in idiopathic pulmonary fibrosis
Official title: Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
Run by University of Virginia · NCT06853145 · Data updated 2026-11-12
This will test whether inhaling hyperpolarized xenon‑129 during MRI can safely show lung ventilation and perfusion changes over time in people with idiopathic pulmonary fibrosis.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 6 (estimated) |
| Sponsor | University of Virginia Academic / other |
| Locations | 1 site (Charlottesville, Virginia) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2027 |
| Registry record updated | July 9, 2025 |
| Trial ID | NCT06853145 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a clinical diagnosis of idiopathic pulmonary fibrosis who can tolerate MRI, are not on continuous home oxygen, and meet oxygen saturation and safety criteria are ideal candidates.
✕Probably not a fit
People who require continuous home oxygen, have oxygen saturation below 92% on the scan day, or have MRI‑incompatible implants or other contraindications are unlikely to be eligible or benefit from this imaging procedure.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase interventional protocol uses inhaled hyperpolarized xenon‑129 gas with MRI to produce high-resolution maps of lung ventilation and perfusion in patients with idiopathic pulmonary fibrosis (IPF). Eligible adults with a clinical diagnosis of IPF who meet MRI safety and oxygenation criteria will undergo the xenon‑129 MRI procedure, which can be repeated over time to track changes. The primary aim is to demonstrate feasibility and reproducibility of longitudinal imaging in this population without requiring continuous home oxygen. Results would inform whether xenon‑129 MRI can be used as a quantitative imaging endpoint in future mechanistic or therapeutic trials.
Why it matters
Potential benefit: If successful, this technique could offer a noninvasive imaging biomarker that detects regional lung function changes earlier than conventional tests and help guide treatments for people with IPF.
How similar studies have gone: Hyperpolarized xenon‑129 MRI has shown promise in mapping ventilation and perfusion deficits in COPD and preliminary fibrosis work exists, but longitudinal use as an endpoint in IPF remains novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to provide informed consent 18 years of age or greater Clinical diagnosis of IPF Exclusion Criteria: * Continuous oxygen use at home * Oxygen saturation less than 92% on the day of MRI procedure * Pregnancy or lactation * Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded. * History of congenital cardiac disease, chronic renal failure, or cirrhosis. • Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches. * Inability to understand simple instructions or to hold still for approximately 10-15 seconds. * History of respiratory infection within 2 weeks prior to the MR scan * History of MI, stroke and/or poorly controlled hypertension.
Where it's running
-
Snyder Building 480 Ray C. Hunt Drive
Charlottesville, Virginia, United States Recruiting
Study contacts
- Principal investigator: John Kim, MD — University of Virginia
- Study coordinator: Roselove Asare, MA
- Email: rnn3b@uvahealth.org
- Phone: 4342436074
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
New IPF drug ORJ-001 tested in adults with IPF
A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.
-
Nalbuphine ER for IPF-related chronic cough
This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.
-
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.
-
Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs
This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.
-
Rentosertib by mouth for people with idiopathic pulmonary fibrosis
This is a randomized, placebo-controlled test to see if Rentosertib helps adults with idiopathic pulmonary fibrosis when taken as a pill.
-
Inhaled nintedanib powder for IPF in adults
This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.